JPWO2020154252A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020154252A5 JPWO2020154252A5 JP2021542124A JP2021542124A JPWO2020154252A5 JP WO2020154252 A5 JPWO2020154252 A5 JP WO2020154252A5 JP 2021542124 A JP2021542124 A JP 2021542124A JP 2021542124 A JP2021542124 A JP 2021542124A JP WO2020154252 A5 JPWO2020154252 A5 JP WO2020154252A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- treatment
- fenebrutinib
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 38
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 claims 13
- 229950009618 fenebrutinib Drugs 0.000 claims 13
- 208000024891 symptom Diseases 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 8
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 229940124624 oral corticosteroid Drugs 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 claims 1
- 108050001540 High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940033495 antimalarials Drugs 0.000 claims 1
- 229960000106 biosimilars Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229950006348 sarilumab Drugs 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062648A JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2025189049A JP2026041743A (ja) | 2019-01-22 | 2025-11-10 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795477P | 2019-01-22 | 2019-01-22 | |
| US62/795,477 | 2019-01-22 | ||
| US201962913270P | 2019-10-10 | 2019-10-10 | |
| US62/913,270 | 2019-10-10 | ||
| PCT/US2020/014346 WO2020154252A1 (en) | 2019-01-22 | 2020-01-21 | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062648A Division JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523018A JP2022523018A (ja) | 2022-04-21 |
| JPWO2020154252A5 true JPWO2020154252A5 (https=) | 2023-02-01 |
| JP2022523018A5 JP2022523018A5 (https=) | 2023-02-01 |
Family
ID=69726724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542124A Pending JP2022523018A (ja) | 2019-01-22 | 2020-01-21 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2024062648A Pending JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2025189049A Pending JP2026041743A (ja) | 2019-01-22 | 2025-11-10 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062648A Pending JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2025189049A Pending JP2026041743A (ja) | 2019-01-22 | 2025-11-10 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12544372B2 (https=) |
| EP (1) | EP3914250A1 (https=) |
| JP (3) | JP2022523018A (https=) |
| KR (1) | KR20210119457A (https=) |
| CN (3) | CN113423401A (https=) |
| AU (2) | AU2020213265B2 (https=) |
| CA (1) | CA3125236A1 (https=) |
| IL (1) | IL284779A (https=) |
| MX (2) | MX2021008696A (https=) |
| TW (1) | TW202042815A (https=) |
| WO (1) | WO2020154252A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021249129A1 (en) | 2020-04-03 | 2022-10-20 | F. Hoffmann-La Roche Ag | Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase |
| WO2024235166A1 (zh) * | 2023-05-12 | 2024-11-21 | 武汉人福创新药物研发中心有限公司 | 含有btk抑制剂的组合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362591B (es) * | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| EP4049660B1 (en) | 2016-02-29 | 2025-02-19 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| JP2020514384A (ja) | 2017-03-24 | 2020-05-21 | ジェネンテック， インコーポレイテッド | 自己免疫及び炎症性疾患を治療する方法 |
-
2020
- 2020-01-21 CN CN202080010603.3A patent/CN113423401A/zh active Pending
- 2020-01-21 MX MX2021008696A patent/MX2021008696A/es unknown
- 2020-01-21 EP EP20708271.0A patent/EP3914250A1/en active Pending
- 2020-01-21 TW TW109102194A patent/TW202042815A/zh unknown
- 2020-01-21 JP JP2021542124A patent/JP2022523018A/ja active Pending
- 2020-01-21 CN CN202410640589.5A patent/CN118662512A/zh active Pending
- 2020-01-21 CN CN202410639156.8A patent/CN118453606A/zh active Pending
- 2020-01-21 WO PCT/US2020/014346 patent/WO2020154252A1/en not_active Ceased
- 2020-01-21 AU AU2020213265A patent/AU2020213265B2/en active Active
- 2020-01-21 CA CA3125236A patent/CA3125236A1/en active Pending
- 2020-01-21 KR KR1020217026474A patent/KR20210119457A/ko active Pending
-
2021
- 2021-07-12 IL IL284779A patent/IL284779A/en unknown
- 2021-07-19 MX MX2025013950A patent/MX2025013950A/es unknown
- 2021-07-21 US US17/381,592 patent/US12544372B2/en active Active
-
2024
- 2024-04-09 JP JP2024062648A patent/JP2024099575A/ja active Pending
-
2025
- 2025-03-17 AU AU2025201888A patent/AU2025201888A1/en active Pending
- 2025-11-10 JP JP2025189049A patent/JP2026041743A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11344545B2 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| RU2770050C2 (ru) | Способ лечения с применением традипитанта | |
| US20180117148A1 (en) | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders | |
| EP2969001B1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| Zeng et al. | LB0001 head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study | |
| EP1471916B1 (en) | Treatment of rheumatoid arthritis using imatinib | |
| JP2023536944A (ja) | 疾患の治療におけるｂｔｋ阻害剤の使用 | |
| Karanikolas et al. | Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. | |
| EP1884245A1 (en) | Use of Escin | |
| JPWO2020154252A5 (https=) | ||
| JP7186214B2 (ja) | 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 | |
| WO2020106191A1 (ru) | Производное глутаримида для преодоления резистентности к стероидам | |
| WO2021108338A1 (en) | A combination of a btk inhibitor and abatacept for the treatment of rheumatoid arthritis | |
| RU2837046C1 (ru) | Применение ингибиторов btk при лечении заболеваний | |
| WO2011151372A1 (en) | Treatment of rheumatoid arthritis with masitinib | |
| WO2024173749A1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis | |
| CN110891580A (zh) | 使用三氧化二砷治疗多发性硬化症的方法 | |
| Rejón et al. | Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement | |
| Bloxham | 9.1 Learning Outcomes | |
| WO2025221754A1 (en) | Upadacitinib for use in the treatment of giant cell arteritis | |
| CN108478581A (zh) | 防治运动病、梅尼埃病的药物及托伐普坦的医药用途 | |
| RU2810253C2 (ru) | Способ лечения с применением традипитанта | |
| JP2003063995A (ja) | 免疫学的疾患の治療のための配合製剤 | |
| EP1773340A2 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition | |
| JP2025513444A (ja) | 自己免疫性皮膚疾患の治療 |